Literature DB >> 15569976

Dendritic cell infiltration and prognosis of early stage breast cancer.

Isabelle Treilleux1, Jean-Yves Blay, Nathalie Bendriss-Vermare, Isabelle Ray-Coquard, Thomas Bachelot, Jean-Paul Guastalla, Alain Bremond, Sophie Goddard, Jean-Jacques Pin, Clarisse Barthelemy-Dubois, Serge Lebecque.   

Abstract

PURPOSE: Although dendritic cells (DC) and T cells can infiltrate primary breast carcinoma, it remains unclear whether the immune response influences the clinical outcome. EXPERIMENTAL
DESIGN: T lymphocytes and DC infiltration within primary tumors was investigated in 152 patients with invasive nonmetastatic breast cancer. CD1a, CD3, CD68, CD123, CD207/Langerin, and CD208/DC-LAMP expression was assessed with semiquantitative immunohistochemical analysis. Expression of chemokines involved in DC migration (MIP-3a/CCL20, MIP-3b/CCL19, and 6Ckine/CCL21) was also examined. The correlation between these markers and the characteristics of the tumors, as well as relapse-free and overall survival was analyzed. Significant prognostic parameters were then tested in a validation series.
RESULTS: Infiltration by immature CD207/Langerin+ DC was found in a third of the cancers and did not correlate with clinicopathological data. Presence of mature CD208/DC-LAMP+ DC (56%) and CD3+ T cells (82%) strongly correlated with lymph node involvement and tumor grade. Among the chemokines analyzed, only the presence of MIP-3b/CCL19 in 57% of the tumors correlated with prolonged overall survival. CD123+ plasmacytoid DC (pDC) infiltrated 13% of the primary tumors. Their presence was strongly associated with shorter overall survival (93% versus 58% at 60 months) and relapse-free survival (90% versus 37% at 60 months) and was found to be an independent prognostic factor for overall survival and relapse-free survival and confirmed in an independent validation series of 103 patients.
CONCLUSIONS: Infiltration by pDC of primary localized breast tumor correlates with an adverse outcome, suggesting their contribution in the progression of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15569976     DOI: 10.1158/1078-0432.CCR-04-0684

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  156 in total

1.  Papillary thyroid carcinoma behavior: clues in the tumor microenvironment.

Authors:  Kensey Bergdorf; Donna C Ferguson; Mitra Mehrad; Kim Ely; Thomas Stricker; Vivian L Weiss
Journal:  Endocr Relat Cancer       Date:  2019-06       Impact factor: 5.678

2.  Impact of tumor-infiltrating LAMP-3 dendritic cells on the prognosis of esophageal squamous cell carcinoma.

Authors:  Junya Nishimura; Hiroaki Tanaka; Yoshihito Yamakoshi; Soichiro Hiramatsu; Tatsuro Tamura; Takahiro Toyokawa; Kazuya Muguruma; Kiyoshi Maeda; Kosei Hirakawa; Masaichi Ohira
Journal:  Esophagus       Date:  2019-04-09       Impact factor: 4.230

Review 3.  Mechanisms of aromatase inhibitor resistance.

Authors:  Cynthia X Ma; Tomás Reinert; Izabela Chmielewska; Matthew J Ellis
Journal:  Nat Rev Cancer       Date:  2015-05       Impact factor: 60.716

Review 4.  Antitumour actions of interferons: implications for cancer therapy.

Authors:  Belinda S Parker; Jai Rautela; Paul J Hertzog
Journal:  Nat Rev Cancer       Date:  2016-03       Impact factor: 60.716

5.  Many Roles of CCL20: Emphasis on Breast Cancer.

Authors:  Kingsley O Osuala; Bonnie F Sloane
Journal:  Postdoc J       Date:  2014-03

Review 6.  A pathogenic role of plasmacytoid dendritic cells in autoimmunity and chronic viral infection.

Authors:  Franck J Barrat; Lishan Su
Journal:  J Exp Med       Date:  2019-08-16       Impact factor: 14.307

7.  Distribution of dendritic cell subtypes in primary oral squamous cell carcinoma is inconsistent with a functional response.

Authors:  Rebekah K O'Donnell; Rosemarie Mick; Michael Feldman; Satoshi Hino; Yan Wang; Marcia S Brose; Ruth J Muschel
Journal:  Cancer Lett       Date:  2007-06-18       Impact factor: 8.679

Review 8.  Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade.

Authors:  Leisha A Emens
Journal:  Expert Rev Anticancer Ther       Date:  2012-12       Impact factor: 4.512

9.  Tumor-infiltrating regulatory dendritic cells inhibit CD8+ T cell function via L-arginine metabolism.

Authors:  Lyse A Norian; Paulo C Rodriguez; Leigh A O'Mara; Jovanny Zabaleta; Augusto C Ochoa; Marina Cella; Paul M Allen
Journal:  Cancer Res       Date:  2009-03-17       Impact factor: 12.701

10.  A novel cancer vaccine strategy based on HLA-A*0201 matched allogeneic plasmacytoid dendritic cells.

Authors:  Caroline Aspord; Julie Charles; Marie-Therese Leccia; David Laurin; Marie-Jeanne Richard; Laurence Chaperot; Joel Plumas
Journal:  PLoS One       Date:  2010-05-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.